The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2022 | The future of CAR-T therapy: earlier use, new indications, & improved manufacturing
Christian Buchholz, PhD, Paul-Ehrlich-Institut, Langen, Germany, discusses advances in chimeric antigen receptor T-cell (CAR-T) therapy. Originally approved in B-cell precursor acute lymphoblastic leukemia (B-ALL), new CAR-T approaches are now being developed for a wider range of indications including other lymphoma subtypes and multiple myeloma. In addition, whilst CAR-Ts have only been approved in the third-line setting in lymphoma, there is an increasing body of evidence suggesting that these cellular therapies might be beneficial in earlier lines of treatment. In parallel, Dr Buchholz explains that companies are working on decreasing CAR-T manufacturing costs, thus making this treatment available for a larger number of patients. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
